651734-54-2

Usage

Uses

Used in Pharmaceutical Industry:
2,6-difluoro-3,5-diMethoxybenzenaMine is utilized as a building block for the synthesis of various organic compounds and drugs, contributing to the development of novel pharmaceuticals with improved therapeutic properties.
Used in Medicinal Chemistry:
Due to its distinctive chemical structure, 2,6-difluoro-3,5-diMethoxybenzenaMine serves as a key intermediate in the design and synthesis of new medicinal agents, potentially leading to the discovery of innovative treatments for various diseases.
Used in Organic Chemistry:
2,6-difluoro-3,5-diMethoxybenzenaMine's reactivity and functional groups make it a versatile component in organic synthesis, allowing for the creation of a wide range of chemical products with diverse applications.
Used as a Research Reagent in Laboratories:
2,6-difluoro-3,5-diMethoxybenzenaMine is employed in research settings to study chemical reactions and explore the synthesis of new pharmaceuticals, furthering scientific understanding and driving innovation in the field.

Upstream product

• 651734-52-0 4-(benzylamino)-3,5-difluoro-2,6-dimethoxybenzoic acid 
• 122590-82-3 methyl N-benzyl-4-amino-2,3,5,6-tetrafluorobenzoate 
• 36629-42-2 methyl pentafluorobenzoate 
• 602-94-8 Pentafluorobenzoic acid 
• 651734-56-4 2,6-difluoro-3,5-dimethoxybenzoic acid 
• 651734-55-3 methyl 2,6-difluoro-3,5-dimethoxybenzoate 
• 2150-37-0 methyl 3,5-dimethoxybenzoate 
• 651734-57-5 tert-butyl (2,6-difluoro-3,5-dimethoxyphenyl)carbamate 

Downstream Products

• 651735-08-9 C₁₄H₁₄F₂N₄O₂S 
• 1614233-82-7 6-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[4,3-c]pyridine 
• 1614233-49-6 7-[6-(2,6-difluoro-3,5-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-(methylsulfonyl)-1,2,3,4-tetrahydroisoquinoline 
• 1614234-28-4 tert-butyl 7-[6-(2,6-difluoro-3,5-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 1614233-69-0 2-(2,6-difluoro-3,5-dimethoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 1614233-70-3 6-(2,6-difluoro-3,5-dimethoxyphenyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidine 
• 1614233-72-5 6-(2,6-difluoro-3,5-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidine 
• 1614233-71-4 6-(2,6-difluoro-3,5-dimethoxyphenyl)-3-iodo-1H-pyrazolo[3,4-d]pyrimidine 
• 1614232-51-7 5-[6-(2,6-difluoro-3,5-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-N,N-dimethyl-2,3-dihydro-1-benzofuran-2-carboxamide 
• 1513857-77-6 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3’,2’:5,6]pyrido[4,3-d]pyrimidin-2-one 

Relevant academic research and scientific papers

DERIVATIVES OF AN FGFR INHIBITOR

The present disclosure relates to derivatives (e.g., hydroxyl, keto, glucuronide, sulfonic acid, and deuterated) of a Fibroblast Growth Factor Receptors (FGFR) inhibitor, including methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of FGFR mediated disease such as cancer.

HETEROCYCLICS AS INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR

This disclosure relates to heterocyclics as selective inhibitors of the fibroblast growth factor receptor 4 (FGFR-4), in particular relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising said compound.

Heterocyclic compound as FGFR inhibitor, synthesis method and applications thereof

The present invention discloses a heterocyclic compound as an FGFR inhibitor, and a synthesis method thereof, and applications of the heterocyclic compound in preparation of drugs for treating cancers. According to the present invention, the heterocyclic compound as the FGFR inhibitor or the pharmaceutically acceptable salt thereof has high FGFR inhibitory action, and the pharmaceutical composition prepared from the heterocyclic compound has good anticancer effect and wide application range.

SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME

The present disclosure relates to 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one, solid forms and polymorphs thereof, methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of the FGFR-associated or mediated diseases such as cancer.

FGFR4 INHIBITORS

Methods, compounds, pharmaceutical compositions, and methods of preparing medicaments for treating hepatocellular carcinoma having an altered FGFR4 and/or FGF19 status.

[4,5']BIPYRIMIDINYL-6,4'-DIAMINE DERIVATIVES AS PROTEIN KINASE INHBITORS

The invention provides a novel class of compounds of the Formula (I): in which the symbols have the meanings given in the description and claims, to pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prev

USE OF KINASE INHIBITORS TO PROMOTE NEOCHONDROGENESIS

This invention provides methods for utilizing compounds that inhibit cyclin-dependent kinase and tyrosine kinase enzymes in the promotion of neochondrogenesis and the enhancement, protection and repair of cartilage. In certain embodiments the invention relates to methods of using compounds of formula (I): and pharmaceutically acceptable salts thereof, to promote neochondrogenesis, wherein, R1,R2, R3, R4, R5, R6, A, B, D, and E have any of the values defined therefor in the specification.

Kinase inhibitors

This invention provides phenyl-substituted pyrimidopyrimidines, dihydropyrimido-pyrimidines, pyridopyrimidines, naphthyridines, and pyridopyrazines of the general formula: that inhibit cyclin-dependent kinase and tyrosine kinase enzymes, methods and intermediate compounds for their synthesis, as well as pharmaceutical compositions and methods for their use in treating, inhibiting or preventing maladies associated with cell proliferative disorders, including angiogenesis, atherosclerosis, restenosis, and cancer.